Watch this Weeks Episode Saturday at 9am CT
BCG is one of the most fascinating stories in modern urology. Originally developed as a vaccine against tuberculosis, Bacillus Calmette-Guérin eventually became an important immunotherapy for selected patients with non-muscle-invasive bladder cancer. In this edition of UroNurse News, Vic Senese, RN, BSN, FAUNA, takes you through The Story of BCG — from its development by Albert Calmette and Camille Guérin in the early 20th century to the landmark use of intravesical BCG for bladder cancer.
BCG was developed from an attenuated strain of Mycobacterium bovis and became a tuberculosis vaccine. Researchers later discovered that BCG could stimulate immune responses against cancer. In 1976, Dr. Álvaro Morales and colleagues reported the use of BCG directly inside the bladder for recurrent superficial bladder tumors. That discovery helped establish intravesical BCG as a major treatment for non-muscle-invasive bladder cancer. Subsequent clinical trials demonstrated reductions in bladder cancer recurrence, helping establish BCG as an important form of cancer immunotherapy.
In this episode, we explore:
🔹 The origins of BCG
🔹 Albert Calmette and Camille Guérin
🔹 How a TB vaccine became cancer immunotherapy
🔹 Dr. Álvaro Morales and the landmark 1976 study
🔹 Why BCG is placed directly into the bladder
🔹 How BCG stimulates the immune system
🔹 Why BCG remains important in bladder cancer treatment
🔹 What happens when bladder cancer becomes BCG-unresponsive
The story of BCG demonstrates how unexpected discoveries can transform medicine.
Subscribe to the UroNurse YouTube channel for more urology education, men's health information, medication discussions, bladder health, prostate health, sexual health and the latest urology news: Subscribe to UroNurse on YouTube
*The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.
Click on image to visit our sponsor's website.
Click below for sponsorship info.
Episode 216: Immunotherapy in Bladder Cancer: Practice-Changing Advances Every Urology Professional Should Know
CME | CNE |1.00 Credit
Episode 201: Unraveling the Complexities of cUTI Care: Modernizing cUTI Care with the 2025 IDSA and EAU Updates
CME | CNE | CPE | 1.00 CreditEpisode 196: Opportunistic Pathogens in Healthcare: Hidden Threats Every Nurse Must Know
Click for Contact HoursEpisode 184: Optimizing Urothelial Carcinoma Therapy: From Maintenance to Precision Strategies
1.00 / CME Contact Hour183: Optimizing Care in Advanced Renal Cell Carcinoma: Immunotherapy & Targeted Agents Explained
1.00 / ANCC Contact Hour179: The Future of Prostate Cancer Care: New Treatments Explained for Urology Nurses
1.00 / ANCC Contact HourThe information provided on the site is for educational purposes only, and does not substitute for professional medical advice.
Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.